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1. INTRODUCTION 
1.1. DRUG INTERACTION 
Drug Interaction is desirable or undesirable pharmacological effect of drugs 
interacting with other drugs, with endogenous physiologic chemical agents, with 
components of the diet, and with chemicals used in diagnostic tests or the results of such 
tests.An interaction can either increase or decrease the effectiveness and/or the side 
effects of a drug, or it can create a new side effect not previously seen before. Drug 
interactions may make the drug less effective, cause unexpected side effects or increase 
the action of a particular drug. Some drug interactions can even be harmful. Therefore, 
reading the label every time before using a nonprescription or prescription drug and 
taking the time to learn about drug interactions may be useful. The probability of 
interactions increases with the number of drugs taken. The high rate of prescribed drugs 
in elderly patients (65-year-old patients take an average of 5 drugs) increases the 
likelihood of drug interactions and thus the risk that drugs itself can be the cause of 
hospitalization. 
1.1.1. RELEVANCE OF DRUG INTERACTIONS 
The desirable and undesirable effects of a drug are related to its concentration at 
various sites of action, which is usually related to the blood or tissue concentration of the 
drug. The blood or tissue concentrations resulting from a dose are determined by the 
drug’s absorption, distribution, metabolism, and excretion (ADME). Elimination of a 
drug or its active metabolites occurs either by metabolism to an inactive metabolite that 
is excreted, or by direct excretion of the drug or active metabolites. The kidneys and liver 
are responsible for most drug excretion. Drug interactions related to metabolism and 
excretion are well-recognized, but effects related to transporters are being documented 
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with increasing frequency and are, therefore, important to consider in drug development. 
Therapeutic proteins may be eliminated through a specific interaction with cell surface 
receptors, followed by internalization and lysosomal degradation within the target cell. 
The overall objective of interaction studies for a new drug is to determine: 
 Whether any interactions are sufficiently large to necessitate a dosage 
adjustment of the drug itself or of the drugs with which it might be used 
 Whether any interaction calls for additional therapeutic monitoring, or 
 Whether there should be a contraindication to concomitant use when lesser 
measures 269 cannot mitigate risk. 
1.1.2. DRUG INTERACTION OCCURS: 
When there is an increase or decrease in: 
- The absorption of a drug into the body 
- Distribution of the drug in the body 
- Changes made to the drug through the body’s metabolism 
- Elimination of the drug from the body 
Drug interactions fall into three broad categories: 
1.1.2.1 Drug-drug interactions 
Drug-drug interactions (DDIs) occur when the effects of a drug are changed by 
the presence of another drug, resulting in synergistic, additive or antagonistic outcomes 
and are an important cause of preventable adverse drug events.
1
 For example, mixing a 
drug you take to help you sleep (a sedative) and a drug you take for allergies (an 
antihistamine) can slow your reactions and make driving a car or operating machinery 
dangerous. 
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1.1.2.2. Drug-food/beverage interactions 
A drug-food interaction happens when the food affects the ingredients in a 
medicine which the patient is taking affecting the efficacy of medicine being 
administered.
2
 For example, mixing alcohol with some drugs may cause you to feel tired 
or slow your reactions. 
1.1.2.3. Drug-disease interactions 
Drug disease interaction may occur when an existing medical condition makes 
certain drugs potentially harmful. For example, if you have high blood pressure you 
could experience an unwanted reaction if you take a nasal decongestant. 
1.2. DRUG – DRUG INTERACTIONS 
Drug-drug interaction (DDI) is one of the kind of drug related problems in which 
effects of one drug can be altered by the co-administration of another drug. DDIs are 
termed as pharmacological and clinical outcomes resulted from simultaneous use of 
different combinations of drugs as compared to their use alone. These DDIs could result 
in serious life threatening conditions in a desire to alter the therapeutic end point of 
drugs. DDI is said to account for a number of severe ADR resulting in hospitalizations 
and emergency department visits. It is estimated that, in 2011 DDI contribute to about 
56.4% of all ADR.
3 
Furthermore, ADR due to DDI accounts to about 2.8% hospital 
admission every year.
4
Many adverse events can be prevented by identifying potential 
drug interactions. However, certain conditions such as multiple disorders, chronic 
diseases and polypharmacy may increase the risk of pDDIs.It was reported in 2011 that 
164 (75.9%) patients taking 7 or more drugs were having at least one pDDIs while 76 
(73.8%) patient witha  hospital stay of seven or more were at risk of DDIs.
2 
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1.2.1. TYPES OF DRUG – DRUG INTERACTIONS 
Interactions between drugs may be categorized by : 
• Behavioral drug–drug interactions: 
Occur when one drug alters the patient’s behavior to modify compliance with 
another drug. For example, a depressed patient taking an antidepressant may become 
more compliant with medication as symptoms improve.
5 
•Pharmaceutical drug–drug interactions: 
Occur when the formulation of one drug is altered by another before it is 
administered. For example, precipitation of sodium thiopentone and vecuronium within 
an intravenous giving set. 
• Pharmacokinetic drug–drug interactions: 
Occur when one drug changes the systemic concentration of another drug, 
altering ‘how much’ and for ‘how long’ it is present at the site of action. 
• Pharmacodynamic drug–drug interactions: 
Occur when interacting drugs have either additive effects, in which case the 
overall effect is increased, or opposing effects, in which case the overall effect is 
decreased or even ‘cancelled out’.5   
1.2.1.1. PHARMACOKINETIC DRUG INTERACTION 
1.2.1.1.1. ABSORPTION 
Gastro-intestinal absorption 
The complexity of the gastro-intestinal tract and the effects of several drugs with 
functional activity in the digestive system represent favorable conditions for the 
emergence of DDI that may alter the drug bioavailability.
6 
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Several factors may influence the absorption of a drug through the 
gastrointestinal mucosa. The first factor is the change in gastric pH. The majority of 
drugs orally administered require, to be dissolved and absorbed, a gastric pH between 2.5 
and 3. Therefore, drugs able to increase gastric pH (i.e., antacids, anticholinergics, proton 
pump inhibitors [PPI] or H2-antagonists) can change the kinetics of other co-
administered drugs. 
In fact, H2 antagonists (e.g., ranitidine), antacids (e.g., aluminium hydroxide and 
sodium bicarbonate) and PPI (e.g., omeprazole, esomeprazole, pantoprazole) that 
increase the gastric pH lead to a decrease in cefpodoxime bioavailability, but on the other 
hand, facilitate the absorption of beta-blockers and tolbutamide. 
Moreover, antifungal agents (e.g., ketoconazole or itraconazole), requires an 
acidic environment for being properly dissolved, therefore, their co-administration with 
drugs able to increase gastric pH, may cause a decrease in both dissolution and 
absorption of antifungal drugs.
7
 Therefore, antacid or anticholinergics, or PPI might be 
administered at least 2 h after the administration of antifungal agents.
8
Similarly, the 
administration of drugs able to increase the gastric pH with ampicillin, atazanavir, 
clopidogrel, diazepam, methotrexate, vitamin B12, paroxetine and raltegravir are not 
recommended. 
In contrast, the ingestion of drugs that cause a decrease in gastric pH (e.g., 
pentagastrin) may have an opposite effect. It is worth noting that severity of DDIs caused 
by alteration of gastric pH mainly depends on pharmacodynamics characteristics of the 
involved drug, in terms of narrow therapeutic range. 
Another factor that modifies the drug absorption is the formation of complexes. 
In this case, tetracyclines (e.g., doxycycline or minocycline) in the digestive tract can 
combine with metal ions (e.g., calcium, magnesium, aluminum, iron) to form complexes 
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poorly absorbed. Consequently certain drugs (e.g., antacids, preparations containing 
magnesium salts, aluminum and calcium preparations containing iron) can significantly 
reduce the tetracyclines absorption.
9
Analogously; antacids reduce the absorption of 
fluoroquinolones (e.g., ciprofloxacin), penicillamines and tetracyclines, because the 
metal ions form complexes with the drug. In agreement, was observed that antacids and 
fluoroquinolones should be administered at least 2 h apart or more.
10, 11 
Cholestyramine and colestipol bind bile acids and prevent their absorption in the 
digestive tract,
 12
 but they can also bind other drugs, especially acidic drugs (e.g., 
warfarin, acetyl salicylic acid, sulfonamides, phenytoin, and furosemide). Therefore, the 
interval between the administration of cholestyramine or colestipol and other drugs may 
be as long as possible (preferably 4 h).
13
 
Motility disorders represent the third factor involved in absorption DDIs. Drugs 
able to increase the gastric transit (e.g., metoclopramide, cisapride or cathartic) can 
reduce the time of contact between drug and mucosal area of absorption inducing a 
decrease of drug absorption (e.g., controlled-release preparations or entero-protected 
drugs).
14
 
For example, metoclopramide, may accelerate gastric emptying, hence decreasing 
the absorption of digoxin and theophylline whereas it can accelerate the absorption of 
alcohol, acetylsalicylic acid, acetaminophen, tetracycline and levo-dopa.
15
 Finally, iron 
can inhibits the absorption of levodopa and methyldopa. 
Modulation of P-glycoprotein (P-gp) intestinal 
P-gp or gp-120 for its molecular weight, is a transmembrane protein encoded by 
the human multidrug resistance gene-1 belonging to the adenosine triphosphate-binding 
cassette (ABC) superfamily, together with other 41 members grouped in 7 families (A to 
G).
16
 Localized in liver, pancreas, kidney, small and large intestine, adrenal cortex, testes 
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and leukocytes, P-gp plays a protective role influencing the trans membrane drugs 
diffusion thus reducing their absorption or increasing their excretion or limiting their 
tissues distribution (i.e., central nervous system, foetal and gonadic tissues).
17
 
P-gp regulates the intestinal absorption of drugs (it is present on the luminal 
surface of enterocytes) and promotes their excretion (it is present on the side tubular of 
epithelium renal and biliary side of hepatocytes). Therefore, the administration of drugs 
able to stimulate to inhibit the activity of P-gp can induce the development of DDI. 
The P-gp inhibition can significantly increase the bioavailability of drugs poorly 
absorbed.
18
 
Among the interactions studied at the time of this review, it is worth mentioning 
the effects of terfenadine on the transport of doxorobucin as well as the effects 
chlorpromazine and progesterone on the transport of cyclosporine.
19
 The DDIs on P-gp 
might induce a clinical effect in presence of drugs with a low therapeutic index (e.g., 
digoxin, theophylline, anticancer drugs) when co-administered with macrolides (e.g., 
erythromycin, roxithromycin, clarithromycin), PPIs (e.g., omeprazole or esomeprazole) 
or anti-arrhythmic drugs (e.g., dronaderon, amiodarone, verapamil or diltiazem). 
Many drugs (but not all) that are transported by P-gp are also metabolized by 
cytochrome P450 (CYP) isoform 3A4 (e.g., cyclosporine, antiepileptic drugs, 
antidepressant, fluoroquinolones, quinidine and ranitidine), which can confound 
interpretation of interactions .Therefore, the co-administration of these drugs with known 
inhibitors of P-gp above described results in a clinically evident DDI. 
Recently, it has been described that aripiprazole and its active metabolite, 
dehydroaripiprazole, but no risperidone, paliperidone, olanzapine and ziprasidone are 
strong P-gp inhibitors, in vitro, while in vivo their administration is unlikely to induce 
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DDIs at the blood-brain-barrier, but the possibility of DDIs in the intestine cannot be 
neglected. 
However, it is important to underline that a DDI could be also used in clinical 
management. In fact, Shi et al.
20
 documented that sildenafil inhibits the transporter 
function of P-gp, suggesting a possible strategy to enhance the distribution and 
potentially the activity of anticancer drugs. 
1.2.1.1.2. DISTRIBUTION 
Usually, drugs are transported through a binding to plasma and tissues proteins. 
Of the many plasma proteins interacting with drugs, the most important are albumin, α1-
acid glycoprotein, and lipoproteins. Acidic drugs are usually bound more extensively to 
albumin, while basic drugs are usually bound more extensively to α1-acid glycoprotein, 
lipoproteins, or both. Only unbound drug is available for passive diffusion to 
extravascular or tissue sites and typically determines drug concentration at the active site 
and thus its efficacy. Albumin represents the most prominent protein in plasma, it is 
synthesized in the liver and distributed in both plasma and extracellular fluids of skin, 
muscles and various tissues. Intestinal fluid albumin concentration is about 60% of that 
in the plasma. Since albumin has five binding sites (i.e., for warfarin, benzodiazepines, 
digoxin, bilirubin and tomoxifen), the main characterized are the site I and II.
21
 
Site I, also known as the warfarin binding site, is formed by a pocket in 
subdomain IIA, while site II located in subdomain IIIA is known as the benzodiazepine-
binding site. Ibuprofen and diazepam are selective drug probes for site II.
22,23,24
 
As the free molecules interact with their molecular targets and are metabolized, 
other molecules come into solution to reach the site of action. The degree of plasma 
protein binding, expressed by the ratio of bound drug concentration/free drug 
concentration, varies greatly among drugs, possibly reaching very high values, especially 
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when it is greater than 0.9, otherwise it is considered to be low (<0.2). Drugs that have a 
high degree of plasma protein binding are potentially more likely to be displaced by drug 
with greater affinity for the same binding site. From a mere clinical point of view, that 
displacement could be associated with symptoms, side effects or toxicities when the 
displaced drug has a higher degree of binding to plasma proteins (>90%), reduced 
volume of distribution, narrow therapeutic index, and it is characterized by a faster onset 
of the effect. 
A typical pharmacological displacement can be observed when warfarin and 
diclofenac are co-administered. Warfarin and diclofenac have the same affinity for 
albumin, therefore the administration of diclofenac to a patient treated chronically with 
warfarin results in displacement of latter from its binding site. The increase in plasma 
concentration of free warfarin causes the development of serious hemorrhagic reactions. 
1.2.1.1.3. METABOLISM 
The CYP enzyme family plays a dominant role in the biotransformation of a wide 
number of drugs. In man, there are about 30 CYP isoforms, which are responsible for 
drug metabolism and these belong to families 1-4, but only 6 out of 30 isoforms 
belonging to families CYP1, 2 and 3 (i.e., CYP1A2, 3A4, 2C9, 2C19, 2D6 and 2E1) are 
mainly involved in the hepatic drug metabolism.
25-29
 
The broad range of drugs that undergo CYP mediated oxidative 
biotransformation is responsible for the large number of clinically significant drug 
interactions during multiple drug therapy. Many DDIs are related to the inhibition or 
induction of CYP enzymes. 
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Inhibition 
Inhibition-based DDIs constitute the major proportion of clinically relevant 
DDIs. In this process enzyme activity is reduced due to direct interaction with a drug, 
usually begins with the first dose of the inhibitor, while the extinction of inhibition is 
related to the drug half-lives.
29, 30
 
The metabolic inhibition may be reversible (competitive, metabolic-intermediate 
complex, non-competitive) or irreversible, and clinical effects are influenced by basic 
mechanisms. 
Reversible inhibition 
Competitive 
The competitive inhibition occurs when inhibitor and substrate compete for the 
same binding site on the enzyme. In this type of interaction, the inhibition mechanism is 
direct and is rapidly reversible. 
The drugs are converted through multiple CYP dependent steps to nitroso-
derivatives that bind with high affinity to the reduced form of CYP enzymes. Thus CYP 
enzymes are unavailable for further oxidation and synthesis of new enzymes is, 
therefore, the only means by, which activity can be restored and this may take several 
days.
31
 
It depends on the substrate-versus-inhibitor binding constant ratio, and on the relative 
concentrations of each species. Some of the inhibitors of CYP3A4 that act by this 
mechanism of inhibition include azole antifungal agents, some HIV protease inhibitors 
such as nelfinavirmesylate,
32
and antihypertensives such as diltiazem.
33
In particular, it 
has been reported a two-fold decrease in oral clearance of metoprolol in presence of 
propafenone; therefore, during a co-administration the dose of metoprolol should be 
reduced.
34
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However, recently we reported a case of an 85-year-old woman that developed 
visual hallucinations and psychomotor agitation during the treatment with venlafaxine 
and propafenone.
35 
We postulated a DDI between venlafaxine and propafenone because 
venlafaxine is metabolized primarily by CYP2D6 and is a substrate of P-gp, while 
propafenone is a known substrate and inhibitor of both CYP2D6 and P-gp. Therefore, 
propafenone may be induced an increase of venlafaxine plasma concentrations with the 
development of hallucinations. Similar DDI are seen in the combined administration of 
thioridazine and propranolol (CYP2D6), fluoxetine and desipramine 
(CYP2D6),omeprazole and diazepam (CYP2C19), tolbutamide and phenytoin 
(CYP2C9), and diltiazem and cyclosporin (CYP3A). 
Omeprazole, a CYP2C19 inhibitor, decreases the antiplatelet activity of 
clopidogrel by inhibiting the biotransformation of the clopidogrel pro drug into its active 
metabolite.
36 
In patients hospitalized for acute coronary syndrome, this interaction is 
associated with a 27% increased risk of death or re-hospitalization.
37
 By analogy, 
inhibition of CYP2C19 by etravirine may also inhibit clopidogrel antiplatelet activity. 
Until more data become available, the co-administration of CYP2C19 inhibitors (e.g., 
etravirine and omeprazole) and clopidogrel is not recommended. 
Moreover, omeprazole treatment should be well evaluated in elderly patients due 
the possibility to induce the development of ADR. In fact, previously we reported in an 
elderly man the development of delirium probably related to a DDI between omeprazole 
and amitriptyline through the CYP2C19 inhibition.
38
 
Amiodarone is metabolized by CYP3A4 and 2C8; in vitro is an inhibitor of 
CYP3A4, 1A2, 2C9 and 2D6. Due to its long half-life (about 30 days), the risk of 
interaction must be extended also at the period after the treatment with amiodarone. 
However, the risk of interactions may also depend on its main metabolite, 
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desethylamiodarone, a competitive inhibitor of CYP2D6, an irreversible inhibitor of 
CYP2A6, 3A4, and 2B6 (for formation of covalent bond), a mixed inhibitor of CYP1A1, 
1A2, 2C9 and 2C19.
39
 
Similarly, HIV protease inhibitors (i.e., saquinavir and ritonavir) increase 
sildenafil serum concentrations up to 11-fold.
40
Similarly, it has been recently reported 
that azole antifungal drugs (i.e., ketoconazole, itraconazole, voriconazole and 
posaconazole) are CYP3A inhibitors able to induce DDIs.
41
 In particular posaconazole 
exhibit inhibitory effects upon CYP3A and PGP and at the dosage of 200 mg for 10 days 
can able to reduce from 1.2 to 1.5 fold the steady-state clearance of cyclosporine. 
Moreover, in an open-label study performed in 36 healthy volunteers, the treatment with 
posaconazole (400 mg twice daily) for 14 days increased the plasma concentrations of 
tacrolimus of 2.2-fold, the area under the curve (AUC) of 4.5-fold, and the half-life up to 
7.5 h.
42
 Therefore, the dosage of tacrolimus should be reduced up to 66% of the original 
dose, in the presence of posaconazole. Similar DDI has been documented when azole 
antifungal treatment was administered in patients taking sirolimus or everolimus, 
therefore, empiric dose reductions of 50% may be considered for both sirolimus and 
everolimus. 
However, in a single-centre study enrolling 20 healthy subjects, Kapil et al.,
43
 
documented the lack of a clinically significant CYP3A4 interaction between 
ketoconazole and transdermal delivery of buprenorphine. It is consistent with the 
parenteral administration of a high clearance drug bypassing exposure to gut wall and 
hepatic CYP3A4 first-pass effects. 
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Metabolic-intermediate complexes 
The production of metabolic-intermediate complexes are an unusual form of 
inhibition where the inhibitor binds only to the enzyme-substrate complex. The 
formation of a metabolic-intermediate complexe results from inhibitors that have an N-
alkyl substituent. After the binding of inhibitor, the latter is oxidized by 3A4 and the 
resultant oxidized species of the inhibitor remains complexed with the reduced heme 
group of CYP3A4 forming a complex slowly reversible. Erythromycin is well-known 
CYP3A4 inhibitors that use this mechanism of inhibition, whereas clarythromycin 
display reduced inhibitory effects with a good clinical efficacy.
44
 
Non-competitive 
In the non-competitive mechanism, the inhibitor and substrate do not compete for 
the same active site, because the presence of an allosteric site. Once a ligand binds the 
allosteric site the conformation of the active site changes, its ability to bind the substrate 
decreases and the product formation tails off. Many drugs are non-competitive inhibitors 
of CYP isoforms, as well as omeprazole and lansoprazole, and cimetidine.
45
 The duration 
of this type of inhibition may be longer if new enzymes have to be synthesized after the 
inhibitor drug is discontinued. 
Irreversible inhibition 
The metabolite resulting from the oxidation of the substrate by CYP3A4 becomes 
irreversible and covalently bound to 3A4, thus leading to a permanent inhibition of the 
enzyme. In the case of irreversible inhibition the critical factor is represented by the total 
amount rather than the concentration of the inhibitor to which CYP isoenzyme is 
exposed. Lipophilic and large molecular size drugs are more likely to cause inhibition. 
Two characteristics make a drug susceptible to inhibitory interactions: one metabolite 
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must account for >30-40% metabolism of a drug and that metabolic pathway is catalyzed 
by a single isoenzyme. 
Inhibitor will decrease the metabolism ofthe  substrate and generally lead to 
increased drug effect or toxicity of the substrate. If the drug is a pro drug the effect is 
decreased. 
Garraffo et al. investigated in an open-label study the effects of single-dose 
administration and steady-state concentrations of tipranavir 500 mg and ritonavir 200 mg 
combination on the pharmacokinetics of tadalafil 10 mg.
46
 The authors documented that 
even if the antiretroviral activity of both tipranavir and ritonavir may not be reduced, the 
dose of tadalafil should be reduced at the start of antiretroviral therapy and then a full 
dose can be resumed after steady state is reached. 
The co-administration of 3A4 inhibitors with the hydroxymethylglutaryl-
coenzyme A reductase inhibitors (statins; e.g., simvastatin) could increase the risk of 
myopathy and rhabdomyolysis. However, it is important to understand that during the 
treatment with statins it is possible the development of myopathy also for metabolic 
saturation, in particular during the poly-therapy.
47
 
Metabolic induction 
Drug interactions involving enzyme induction are not as common as inhibition-
based drug interactions, but equally profound and clinically important. Exposure to 
environmental pollutants as well as the large number of lipophilic drugs can result in 
induction of CYP enzymes. The most common mechanism is transcriptional activation 
leading to increased synthesis of more CYP enzyme proteins. The effect of induction is 
simply to increase the amount of P450 present and speed up the oxidation and clearance 
of a drug. 
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The most common enzyme inducers are rifampicin, phenobarbital, phenytoin, 
carbamazepine, and anti-tubercular drugs. 
Rifampicin induces CYP3A enzymes in the liver, although weak induction of 
other CYP enzymes, including, CYP2A6, CYP2C and CYP2B6, have also been noticed. 
Rifampicin increases the elimination of a large number of drugs, although most of them 
are substrates for CYP3A4, such as midazolam, quinidine, cyclosporine A and many 
steroids. 
Metabolism of the affected drug is increased leading to decreased intensity and 
duration of drug effects.
48
 It is rather difficult to predict the time-course of enzyme 
induction because of several factors, including the half-life and the enzyme turnover, 
which determine the time-course of induction. A complicating factor is that the time-
course of induction depends on the time required for enzyme degradation and new 
enzyme production. 
The short half-life of rifampicin results in enzyme induction (CYP3A4, CYP2C), 
apparent within 24 h, whereas phenobarbital, which has a half-life of 3-5 days, requires 
approximately 1 week for induction (CYP3A4, CYP1A2, CYP2C) to become apparent. 
These enzyme-induction reactions also occur with smoking and long-term alcohol or 
drug consumption and can reduce the duration of action of a drug by increasing its 
metabolic elimination. 
Recently, we documented in a patient with epilepsy a DDI between phenobarbital 
and lamotrigine that induced the development of leukopenia and thrombocytopenia. We 
postulated that CYP enzyme induction by phenobarbital could be responsible for the 
production of reactive metabolites of lamotrigine that might be causative for the 
observed hematologic effects.
49
 
1.2.1.1.4. DRUG-DRUG INTERACTIONS DURING EXCRETION 
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The organs and vehicles deputy at the drug excretion (elimination) are kidneys, 
liver, lungs, faeces, sweat, saliva, milk. The excretion through saliva, sweat and lungs 
(for volatile drugs) and milk has little quantitative significance, but the milk is important 
when the drugs can reach the baby during lactation. 
Drugs are excreted mainly through: 
 Renal tubular excretion (glomerular filtration, tubular reabsorption and active 
tubular secretion) 
 Biliary excretion. 
The kidney is the organ responsible for the elimination of drugs and their 
metabolites. The interaction may occur for a mechanism of competition at the level of 
active tubular secretion, where two or more drugs use the same transport system. An 
example is given by NSAIDs that determine the appearance of toxic effects caused by 
methotrexate when the renal excretion of the anti-proliferative drug is blocked.
50
It was 
also demonstrated that amoxicillin decreased the renal clearance of methotrexate. 
Probenecid, a potent inhibitor of the anionic pathway of renal tubular secretion, increases 
of 2.5 times the area under the AUC of oseltamivir. 
However, this competition between drugs can be exploited for therapeutic 
purposes. For example, probenecid can increase the serum concentration of penicillins 
and cephalosporins, delaying their renal excretion and thus saving in terms of dosage. In 
fact, probenecid acts by competitively inhibiting an organic anion transporter in renal 
tubules, thus increasing plasma concentrations of other transporter substrates, while 
reducing their excretion. 
Several drugs are able to interfere with tubular transport. In particular, 
cimetidine, an H2 receptor inhibitor, may influence the tubular secretion of different 
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molecules. Its effect on the influx and the efflux of organic cations through the human 
organic cation transporter ([hOCT1 and hOCT2] and human multidrug and toxin 
extrusion [hMATE1 and hMATE2-K]) could modify other drug serum concentration 
despite a normal renal function. 
Moreover, in vitro study documented that PPIs (i.e., omeprazole, pantoprazole, 
lansoprazole, rabeprazole, and tenatoprazole) are potent hOCT-inhibitors and could 
modulate the transport of metformin. However, the clinical relevance of this DDIs 
maybe clarify. The interactions can also occur during tubular reabsorption. Many drugs, 
when they are in an ionized form in the urine, pass by diffusion in tubular cells. The 
changes in urinary pH, pharmacologically induced, influence the state of ionization of 
certain drugs and may therefore affect the re-absorption from the renal tubule.
51
 
In particular, if the pH of the urine is alkaline the absorption of acidic drugs is 
reduced, while, in the presence of an acidic pH, basic drug absorption is reduced.The 
changes in urinary pH, however, assume practical importance only if the pKa of the 
drug, i.e., the pH at which 50% of the molecules in solution is present in ionized form, is 
between 7.5 and 10.5 for the bases, and between 3.0 and 7.5 for acids. 
In fact, the pKa values can cause appreciable changes in the degree of 
dissociation of the drug. Compounds such as ammonium chloride, tromethamine and 
diuretics, being able to change urine pH, may affect the excretion of several acidic and 
basic drugs, and this interaction may be used to facilitate the removal of drugs from the 
body. On the contrary, the interaction between diuretics and lithium salts can still have 
negative effects on the patient. 
Lithium is a monovalent cation whose excretion is influenced by changes of 
serum sodium. Therefore, a high excretion of sodium induced by chronic treatment with 
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some diuretics such as thiazides, may increase lithium re-absorption, causing serious 
toxic effects from relative over dosage. 
Some acidic and basic drugs to the high degree of ionization are transferred 
through the epithelium of the renal tubule by active transport. The speed transfer of 
molecules depends on the availability of the transporter, a protein that allows the transfer 
through the cellular membranes. Therefore, when two drugs are substrates of the same 
transmembranetransporter they can complete each other, up to the saturation of 
transporter capacity. At that time, the rate of elimination approached to a zero order 
(saturable) process. 
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1. LITERATURE REVIEW 
Lubinga et. al., (2011)
1
 conducted a retrospective study on “Potential drug-drug interactions 
on in-patient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in 
western Uganda: prevalence, clinical importance and associated factors.” The study analysed 
235 randomly selected hospitalization episodes (medication charts and medical notes) from 
MRRH over a 1-year period from January to December 2008. Data on demographics, 
medications, principal diagnosis, co-morbid conditions and the length of hospital stay were 
collected. Epocrates Rx ® was used to identify and classify potential DDIs according to 
mechanism and management strategy. Descriptive statistics were generated and logistic 
regression used to determine associated factors. The study reported overall prevalence of 
potential DDIs was approximately 23% (54 medication charts with at least one potential DDI 
out of 235 hospitalization episodes). Majority was postulated to occur through a 
pharmacodynamic mechanism (10.6%) and most required either “use with caution” (11.9%) 
or “modify treatment/monitor” (10.6%) as a suggested management strategy. After adjusting 
for confounders: age, sex, hospital department and number of co-morbid conditions, a 
principal diagnosis of a cardiovascular disease and having 4 or more medicines on the chart 
were associated with the presence of a potential DDI. The study concluded that potential 
DDIs frequently occur at MRRH although most are not clinically significant. Patients with 
cardiovascular diseases and those who are prescribed multiple medications need to be 
monitored more closely. 
Dirin et. al., (2014)
52 
conducted a study on the Potential drug-drug interactions in 
prescriptions dispensed in community pharmacies and hospital pharmacies in East of Iran. 
Among the 2796 prescriptions analyzed, 1163 (41.6%) had at least one drug interaction case. 
A total of 1576 cases of interactions were found in prescriptions which 66% of interactions 
were classified as type C. They concluded that polypharmacy is an important factor which 
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leads to DDIs, the more the number of items per prescription, the more the likelihood of drug 
interactions occurrence. Survey showed that 48% of prescriptions had 3-4 drug items with an 
average of 4.18 items per prescription. National committee of rational use of drugs reported 
the mean items of drug per prescription were 3.2 in 2007; however, it is decreasing, but is 
still higher than other countries with average of 1.3-2.1 items per prescription. Based on the 
results of some studies, the rates of potential drug interactions for patients receiving two or 
more drugs range from 24.3% to 42%,  therefore, the greater the number of drugs, the higher 
the possibility of DDIs. The most prevalent type of interactions observed in the study was 
type C, accounting for 66% of all interactions observed regarding the settings. Only 0.14% of 
all interactions were due to type X interactions which all of them were from outpatient 
hospital pharmacy.  
Chatsisvili et. al., (2010)
53
 conducted a prospective, descriptive study on “Potential drug-
drug interactions in prescriptions dispensed in community pharmacies in Greece”. A total of 
1,553 handwritten prescriptions were collected. The prescriptions were processed using the 
Drug Interactions Checker within the www.drugs.com database. The identified potential 
DDIs were categorized into two classes, major and moderate, according to their level of 
clinical significance. Overall 213 prescriptions had one or more potential DDIs and a total of 
287 major and moderate DDIs were identified. Potential DDIs were identified in 18.5% of all 
prescriptions. Major DDIs were identified in 1.9% of all prescriptions and represented 10.5% 
of all DDIs detected, whereas moderate DDIs were identified in 16.6% of all prescriptions 
and represented 89.5% of all DDIs detected. The rate of DDIs increased with prescription 
size. The most common drug involved in major DDIs was amiodarone which interacts with 
potassium-wasting diuretics, digoxin, simvastatin and acenocoumarol. An appropriate 
surveillance system for monitoring such interactions should be implemented. 
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Kafeel et. al., (2014)
54
 conducted a study on “Possibility of Drug-Drug Interaction 
inPrescription Dispensed by Community and Hospital Pharmacy.”This study is to analyze the 
use of all subsidized prescription drugs including their use of drug combination generally 
accepted as carrying a risk of severe interactions. It is a cross sectional study, they analyzed 
all prescriptions (n = 1014) involving two or more drugs dispensed to the population (age 
range 4 - 85 years) from all pharmacies, clinics and hospitals. Data were stratified by age and 
sex, and frequency of common interacting drugs. Potential drug interactions were classified 
according to clinical relevance as significance of severity (types A: major, B: moderate, and 
C: minor) and documented evidence (types 1, 2, 3, and 4). The growing use of 
pharmacological agents means that drug interactions are of increasing interest for public 
health. Monitoring of potential drug interactions may improve the quality of drug prescribing 
and dispensing, and it might form a basis for education focused on appropriate prescribing. 
To make the manifestation of adverse interaction subside, management strategies must be 
exercised if two interacting drugs have to be taken with each other, involving: adjusting the 
dose of the object drug; spacing dosing times to avoid the interaction. The pharmacist, along 
with the prescriber has a duty to ensure that patients are aware of the risk of side effects and a 
suitable course of action they should take. They concluded that it is unrealistic to expect 
clinicians to memorize the thousands of drug-drug interactions and their clinical significance, 
especially considering the rate of introduction of novel drugs and the escalating appreciation 
of the importance of pharmacogenomics. Reliable regularly updated decision support systems 
and information technology are necessary to help avert dangerous drug combinations. 
Murtaza et. al., (2015)
55
conducted a study on “Assessment of potential drug–drug 
interactions and its associated factors in the hospitalized cardiac patients.” Drug–drug 
interactions (DDIs) may result in the alteration of therapeutic response. Sometimes they may 
increase the untoward effects of many drugs. Hospitalized cardiac patients need more 
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attention regarding drug–drug interactions due to complexity of their disease and therapeutic 
regimen. This research was performed to find out types, prevalence and association between 
various predictors of potential drug–drug interactions (pDDIs) in the Department of 
Cardiology and to report common interactions. This study was performed in the hospitalized 
cardiac patients at Ayub Teaching Hospital, Abbottabad, Pakistan. Patient charts of 2342 
patients were assessed for pDDIs using Micromedex Drug Information. Logistic regression 
was applied to find predictors of pDDIs. The main outcome measure in the study was the 
association of the potential drug–drug interactions with various factors such as age, gender, 
polypharmacy, and hospital stay of the patients. We identified 53 interacting-combinations 
that were present in total 5109 pDDIs with median number of 02 pDDIs per patient. Overall, 
91.6% patients had at least one pDDI; 86.3%were having at least one major pDDI, and 84.5% 
patients had at least one moderate pDDI.Among 5109 identified pDDIs, most were of 
moderate (55%) or major severity (45%); established(24.2%), theoretical (18.8%) or probable 
(57%) type of scientific evidence. Top 10 common pDDIs included 3 major and 7 moderate 
interactions. Results obtained by multivariate logistic regression revealed a significant 
association of the occurrence of pDDIs in patient with age of 60 years or more (p< 0.001), 
hospital stay of 7 days or longer (p< 0.001) and taking 7 or more drugs (p< 0.001). 
Ayvaz et. al., (2015)
56
 conducted a study “Toward a complete dataset of drug–drug 
interaction information from publicly available sources.”Although potential drug–drug 
interactions (PDDIs) are a significant source of preventable drug-related harm, there is 
currently no single complete source of PDDI information. In the current study, all publically 
available sources of PDDI information that could be identified using a comprehensive and 
broad search were combined into a single dataset. The combined dataset merged fourteen 
different sources including5 clinically-oriented information sources, 4 Natural Language 
Processing (NLP) Corpora, and 5 Bioinformatics/Pharmacovigilance information sources. As 
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a comprehensive PDDI source, the merged dataset might benefit the pharmacovigilance text 
mining community by making it possible to compare the representativeness of NLP corpora 
for PDDI text extraction tasks, and specifying elements that can be useful for future PDDI 
extraction purposes. An analysis of the overlap between and across the data sources showed 
that there was little overlap. Even comprehensive PDDI lists such as Drug Bank, KEGG, and 
the NDF-RT had less than 50% overlap with each other. Moreover, all of the comprehensive 
lists had incomplete coverage of two data sources that focus on PDDIs of interest in most 
clinical settings. Based on this information, we think that systems that provide access to the 
comprehensive lists, such as APIs into RxNorm, should be careful to inform users that the 
lists may be incomplete with respect to PDDIs that drug experts suggest clinicians be aware 
of. In spite of the low degree of overlap, several dozen cases were identified where PDDI 
information provided in drug product labeling might be augmented by the merged dataset. 
Moreover, the combined dataset was also shown to improve the performance of an existing 
PDDI NLP pipeline and a recently published PDDI pharmacovigilance protocol. Future work 
will focus on improvement of the methods for mapping between PDDI information sources, 
identifying methods to improve the use of the merged dataset in PDDI NLP algorithms, 
integrating high-quality PDDI information from the merged dataset into Wikidata, and 
making the combined dataset accessible as Semantic Web Linked Data. 
Rodrigues et. al., (2014)
57
 conducted a study on” Clinical relevancy and risks of potential 
drug–drug interactions in intensive therapy.”This study is to evaluate the potential Drug–
Drug Interactions (pDDI) found in prescription orders of adult Intensive Care Unit (ICU) of a 
Brazilian public health system hospital; quantify and qualify the pDDI regarding their 
severity and risks to the critical patient, using the database from Micromedex. It is a 
Prospective study (January–December of 2011) collecting and evaluating 369 prescription 
orders (convenient sampling), one per patient. The result states that during the study 1844 
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pDDIs were identified and distributed in 405 pairs (medication A · medication B 
combination). There was an average of 5.00 ± 5.06 pDDIs per prescription order, the most 
prevalent being moderate and important interactions, present in 74% and 67%of prescription 
orders, respectively. In total, there were 9 contraindicated, 129 important and 204moderate 
pDDIs. Among them 52 had as a management recommendation to ‘‘avoid concomitant use’’ 
or ‘‘suspension of medication’’, while 306 had as recommendation ‘‘continuous and 
adequatemonitoring’’. The study concluded that the high number of pDDIs found in the study 
combined with the evaluation of the clinical relevance of the most frequent pDDIs in the ICU 
shows that moderate and important interactions are highly incident. As the majority of them 
demand monitoring and adequate management, being aware of these interactions is major 
information for the safe and individualized risk management. 
Bhagavathula et. al., (2014)
58
 conducted prospective cross sectional study on “Prevalence of 
potential drug-drug interactions among internal medicine ward in University of Gondar 
Teaching Hospital, Ethiopia.” Data was collected from medical records and by interviewing 
the patients face to face. Descriptive analysis was conducted for back ground characteristics 
and logistic regression was used to determine the associated risk. A total of 413 potential 
DDIs and 184 types of interacting combination with 4.13 potential DDI per patient were 
identified in the study. Among 413 potential DDIs most were of moderate interaction 61.2% 
(n=253) followed by 26% (n=107) of minor interactions and 12.8% (n=53) of major 
interactions. There was significant association of occurrence of potential DDIs only with 
taking three or more medications. The study concluded that the most prevalent DDI are of 
moderate severity. 
Teixeira et. al., (2012)
59 conducted a cross sectional study on “ Potential Drug-Drug 
Interactions in Prescriptions to Patients over 45 Years of Age in Primary Care, Southern 
Brazil” The study was conducted at 25 Basic Health Units in the city of Maringa´ (southern 
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Brazil) from May to December 2010 involving patients aged 45 or above. The data were 
collected from prescriptions at the pharmacy of the health unit at the time of the delivery of 
medication to the patient. After delivery, the researcher checked the electronic medical 
records of the patient. A total of 827 patients were investigated (mean age: 64.1; mean 
number of medications: 4.4). DDIs were identified in the Micromedex database. The 
prevalence of potential DDIs and major DDIs was 63.0% and 12.1%, respectively. In both the 
univariate and multivariate analyses, the number of drugs prescribed was significantly 
associated with potential DDIs, with an increasing risk from three to five drugs (OR = 4.74; 
95% CI: 2.90–7.73) to six or more drugs (OR = 23.03; 95% CI: 10.42–50.91). Forty drugs 
accounted for 122 pairs of major DDIs, the most frequent of which involved simvastatin 
(23.8%), captopril/enalapril (16.4%) and fluoxetine (16.4%). Based on the findings, the 
estimated prevalence of potential DDIs was high, whereas clinically significant DDIs 
occurred in a smaller proportion. Exposing patients to a greater number of prescription drugs, 
especially three or more, proved to be a significant predictor of DDIs. Prescribers should be 
more aware of potential DDIs. Future studies should assess potential DDIs in primary care 
over a longer period of time. 
Kapp et. al., (2013)
60
 conducted a cross-sectional retrospective study on “Drug interactions 
in primary health care in the George subdistrict, South Africa”. 400 randomly selected patient 
files from four primary care clinics in the George subdistrict were taken for the study. The 
study reported the prevalence of scripts containing at least one moderate potential interaction 
was 42%; severe potential interaction, 5.25%; and contraindicated combinations, 0.5%. The 
most common drugs involved were enalapril, aspirin, ibuprofen, furosemide and fluoxetine. 
The most common implicated drugs in potentially severe interactions were warfarin, aspirin, 
fluoxetine, tramadol and allopurinol. Two contraindicated combinations were found, namely 
verapamil plus simvastatin, and hyoscine butyl bromide plus oral potassium chloride.  
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Seden et. al., (2015)
61
 conducted a study on “Prevalence and type of drug–drug interactions 
involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda” 
A total of 2000 consecutive patients receiving ARVs at the Infectious Diseases Institute, 
Kampala were studied. The most recent prescription for each patient was screened for 
clinically significant DDIs using www.hiv-druginteractions.org. Univariable and 
multivariable logistic regression were used to identify risk factors for DDIs. A screening tool 
was developed using significant risk factors and tested in a further 500 patients. Clinically 
significant DDIs were observed in 374 (18.7%) patients, with a total of 514 DDIs observed. 
Only 0.2% of DDIs involved a contraindicated combination. Comedications commonly 
associated with DDIs were antibiotics (4.8% of 2000 patients), anthelmintics (2.2%) and 
antifungals (3.5%). Patient age, gender, CD4 count and weight did not affect risk of DDIs. In 
multivariable analysis, the patient factors that independently increased risk of DDIs were two 
or more comedications (P < 0.0001), a PI-containing ARV regimen (P < 0.0001), use of an 
anti-infective (P < 0.0001) and WHO clinical stage 3–4 (P = 0.04). A scoring system based on 
having at least two of these risk factors identified between 75% and 90% of DDIs in a 
validation cohort. The study concluded that significant ARV DDIs occur at similar rates in 
resource-limited settings and developed countries; however, the comedications frequently 
causing DDIs differ. Development of tools that are relevant to particular settings should be a 
priority to assist with prevention and management of DDIs. 
Roblek et. al., (2015)
62
 conducted a randomized, double-blind study on “Clinical-pharmacist 
intervention reduces clinically relevant drug–drug interactions in patients with heart failure” 
Patients admitted with HF were screened for clinically relevant DDIs, and randomized to 
control or intervention. Of 213 patients, 51 (mean age, 79 ± 6 years; male, 47%) showed 66 
clinically relevant DDIs and were randomized. For intervention (n = 26) versus control (n = 
25), the number of patients with and the number of DDIs were significantly lower at 
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discharge: 8 vs. 18 and 10 vs. 31; p = 0.003 and 0.0049, respectively. Over a 6 month follow-
up period, 11 control and 9 intervention patients were re-hospitalized or died (p > 0.2 for all). 
No significant differences were seen between control and intervention for patients with 
eGFR<60 mL/min/1.73 m2 (78%) for re-hospitalization or death (10 vs. 7; p = 0.74). The 
study concluded pharmacist intervention significantly reduces the number of patients with 
clinically relevant DDIs, but not clinical endpoints 6 months from discharge. 
Sharma et. al., (2015)
63
 conducted a prospective observational study on “A study of potential 
drug‑drug interactions among hospitalized cardiac patients in a teaching hospital in Western 
Nepal” Study was conducted from May 2012 to August 2012 among hospitalized cardiac 
patients. Cardiac patients who were taking at least two drugs and who had a hospital stay of 
at least 24 h were enrolled. The medications of the patients were analyzed for possible 
interactions using the standard drug interaction database ‑ Micromedex -2 (Thomson 
Reuters) × 2.0. From a total of 150 enrolled patients, at least one interacting drug 
combination was identified among 32 patients. The incidence of potential DDI was 21.3%. A 
total of 48 potentially hazardous drug interactions were identified. Atorvastatin/azithromycin 
(10.4%), enalapril/metformin (10.4%), enalapril/potassium chloride (10.4%), 
atorvastatin/clarithromycin (8.3%) and furosemide/gentamicin (6.3%) were the most common 
interacting pairs. Drugs most commonly involved were atorvastatin, enalapril, digoxin, 
furosemide, clopidogrel and warfarin. Majority of interactions were of moderate severity 
(62.5%) and pharmacokinetic (58.3%) in nature. Increased number of medicines, prolonged 
hospital stays and comorbid conditions were the risk factors found associated with the 
potential DDI. This study highlighted the need of intense monitoring of patients who have 
identified risk factors to help detect and prevent them from serious health hazards associated 
with drug interactions. 
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Kaliamurthy et. al., (2015)
64
conducted a   Study of Drug-Drug Interactions in General 
Medicine Department of a Tertiary Care Hospital. The number of drugs prescribed for each 
patient, drugs taken by the patient and the drug interactions were recorded. The interactions 
between the drugs were assessed using Micromedex software and Stockley’s Drug 
Interaction. The type and severity of prescription with DDIs was also assessed. The number 
of potential DDIs for the study population was 390 and each prescription had at least one 
interaction. Of the total potential DDIs (n=390) identified, majority were of moderate severity 
(n = 257, 65.90%). Most frequent DDI was seen between Metformin + Ranitidine (moderate 
interaction) in 70 prescriptions (50%) and between Ranitidine + Acetaminophen (minor 
interaction) in 48 prescriptions (34.29%). The common major interactions were seen between 
Rabeprazole + Clopidogrel in 4 prescriptions (2.86%), Enalapril + Spironolactone and 
Ciprofloxacin + Tramadol in 3 prescriptions (2.14%). The drug related problems, primarily 
the drug interactions is a permanent patient related risk in hospitals and the utilization of 
computer software has become the best way to identify and prevent them.  
Patel et. al., (2011)
65conducted a study on ‘Potential drug interactions in patients admitted to 
cardiology wards of a south Indian teaching hospital.’ A prospective observational study 
from Oct 2007 to Apr 2008 was carried out in ‘cardiology department’ of a hospital in South 
India. Those patients who were taking at least two drugs and had a hospital stay of at least 48 
hourswere included in the study. The medications of the patients were analyzed for possible 
interactions. Factors associated with pDDI were studied. The actual interactions that were 
observed during the hospital stay in the study subjects were documented. A total of 812 
patients were included in the study. 388 pDDIs were identified among 249 patients. The 
incidence of pDDI was 30.67%. The most common potential interactions were between 
aspirin & heparin (29.38%), and clopidogrel& heparin (7.21%). Drug classes most commonly 
involved were antiplatelets, anticoagulants and diuretics. Majority of interactions were of 
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moderate severity, delayed onset, and pharmacodynamic in nature. Total 68 actual 
interactions were observed in the observed cases. The study identified pDDIs and also 
documented interactions in cardiovascular patients. Factors which had correlation with 
adverse drug interactions were identified. This study highlights the need for screening 
prescriptions of cardiovascular patients for pDDIs and proactive monitoring of patients who 
have identified risk factors; this helps in detection and prevention of possible adverse drug 
reactions. 
Gunasekaran et. al., (2016)
66conducted a study on ‘Occurrence of drug–drug interactions in 
Adama Referral Hospital, Adama city, Ethiopia.’ A retrospective study was done at Adama 
Referral hospital, Adama city, Ethiopia during March–May 2014. 
Medscape online were used for DDIs and ADRs detection purposes. The average number of 
drugs prescribed per person (encounter) in this study was found to be 2.6, showing the 
presence of poly-pharmacy prescribing practice based on WHO recommendations (1.4–2.4). 
With 788 medications prescribed, 267 DDIs were found in this study and 62 (20.7%) were 
categorized as serious DDIs, 95 (31.7%) as significant DDIs, and 110 (36.7%) as minor 
DDIs. DDIs occurrence was also categorized according to the mechanisms, Pharmacokinetic 
and pharmacodynamic interactions; the highest frequency of DDIs was observed in 85 
(31.8%), attributable to metabolism interaction followed by Antagonistic effect in 51 
(21.4%), and Synergistic/Additive effect in 44 (16.5%). It was observed that serious DDIs 
most often caused possible cardiovascular ADRs. The results of the study showed the high 
number of drugs per person compared to the WHO-reported average number of drugs per 
person and occurrence of DDIs associated with severe cardiovascular risk ADRs in the 
Adama Referral Hospital. This study recommends that the drug information center facilities 
and drug prescription validation is done by the pharmacist and the development of 
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pharmacotherapeutic guidelines supporting selection of drugs in Ethiopian hospitals for 
preventing DDIs and ADRs. 
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1. AIM AND OBJECTIVES 
3.1 AIM OF WORK 
            To Assess the potential drug-drug interactions among hospitalized patients 
in cardiac departments in tertiary care hospitals. 
3.2 OBJECTIVES 
 To identify prevalence of potential drug-drug interactions, in cardiology 
department. 
 To identify the types and severity of pDDIs. 
 To make list of most common pDDIs in the hospitalized cardiac patients and 
to determine the risk factors associated with pDDIs in cardiology 
department. 
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2. PLAN OF WORK 
    The proposed work is designed as mentioned below: 
Phase I 
• Literature survey. 
• Obtaining institutional ethical committee clearance. 
• Obtaining consent from hospital authorities. 
• Designing data entry form, patient consent forms. 
Phase II 
• Collection of data’s from hospitalized cardiac patients. 
Phase III 
• To identify the prevalence of pDDIs. 
• To identify the types and severity of pDDIs. 
• To make list of mostcommon pDDIs in the hospitalized cardiac patients and 
to determine the risk factors associated with pDDIs in cardiology 
department. 
• Submission of Report.          
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3. METHODOLOGY 
Study design: 
• It is a prospective  observational study 
Study site: 
• The research work was conducted at tertiary care hospital, Erode, Erode district, 
Tamil Nadu. 
Study period: 
• 6 Months 
   Inclusion criteria: 
• Hospitalized cardiac patients  
• Age groups above 18 years. 
• Prescriptions with two or more drugs prescribed during the hospitalization were 
only selected for the study. 
Exclusion criteria: 
• Out patients. 
• Ayurveda, siddha, and other prescriptions involving alternative system of 
medicine. 
• Age group less than 18 years. 
• Prescription with less than 2 drugs prescribed . 
Source of data: 
The data were collected from case sheets of hospitalized patients and direct patient 
interview from cardiac department. 
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 WORK METHODOLOGY 
• The data was collected from case sheets of hospitalized patients and direct patient 
interview from cardiac department. Demographic information (age and sex), length of 
hospital stay, main diagnosis, number of drugs and details of comorbidities were 
obtained from the clinical records. All medications that were prescribed, including 
routine and pro-re-nata (means as required) medications, were screened for pDDIs. 
 
• pDDIs were detected using the Drug Interactions Checker within Micromedex®-2.7 
and www.drugs.com. The detected pDDIs were classified as major, moderate and 
minor, relying on their severity of clinical significance and crossover checked 
manually for the presence of enough published medical evidence for the recognized 
interacting marketers. Primarily based on the profile of medicines prescribed, the 
DDIs had been recognized and classified in step with the Micromedex
®
- 2.7 and 
www.drugs.com. 
 
• In line with the types, pDDIs has been categorized as:  pharmacokinetics – absorption, 
distribution, metabolism and excretion. Pharmacodynamics – antagonism, synergism, 
additive. In line with severity, pDDIs were labeled as:  major –the consequences are 
probably life threatening or capable of inflicting permanent harm. Moderate- the 
outcomes may also cause deterioration in patients' scientific fame and additional 
treatment or extension of hospital stay. Minor- The consequences are typically 
moderate. the effects can be bothersome or unnoticeable, but need to now not 
considerably affect the healing outcome. Frequencies expressed as possibilities were 
used to summarize sex, diagnosis, number of medication disbursed frequency of 
pDDIs, the drugs concerned with the pDDIs, period of hospital stay and types, 
severity of pDDIs. 
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Table 1: Distribution of drug-drug interactions in cardiology department 
Sl. No. Departments Total number 
of cases 
collected 
Total number 
of cases with 
drug - drug 
interactions 
Total number of 
drug – drug 
interactions 
1. Cardiology 425 360 (84.70%) 856 
 
 
 
Figure 1: Number of Patients having drug-drug interactions 
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Table 2:Gender wise distribution of drug- drug interactions 
Sl.No Gender Frequency (n = 360) Percentage (%) 
1 Male 252 70.00% 
2 Female 108 30.00% 
 
  
 
 
 
 
 
 
  Figure 2: Gender wise distribution of potential drug- drug interactions 
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Table 3: Age wise distribution 
Sl. No. Age (in years) Frequency(n=360) Percentage (%) 
1. 18-30 11  03.05% 
2. 31-45 39  10.83% 
3. 46-59 94  26.11% 
4. 60-70 159  44.16% 
5. Above 70 57 15.83% 
 
 
 
 
 
 
 
 
Figure 3: Age wise distribution 
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Table 4: Number of hospital stay 
Sl.No No. of Hospital 
Stay (in days) 
Frequency (n=360) Percentage (%) 
1 <3 74 20.55% 
2 4 – 6 251 69.72% 
3 <7 31 08.61% 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Number of hospital stays 
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Table 5 Number of prescribed drugs per day 
Sl.No Number of drugs 
prescribed/day 
Frequency (n=360) Percentage% 
1. <4 29 8.05% 
2. 5-6 145 40.27% 
3. >7 186 51.66% 
 
 
 
 
Figure 5: Number of prescribed drugs per day 
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Table 6: Distribution of diseases in cardiology department 
Sl.No Type of diseases Frequency (n=360) Percentage% 
1. Myocardial 
Infarction 
57 15.83% 
2. Angina 
+ 
Diabetes mellitus 
91 
 
25.27% 
3. Hypertension 131 36.38% 
4. Ischaemic Heart 
Disease 
36 10.00% 
5. Coronary Artery 
Disease 
24 06.66% 
6. Chronic Heart 
Failure 
21 05.83% 
 
 
Figure 6: Types of diseases in cardiology department 
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Table 7:Highest potential drug-drug interaction combinations 
 
 
PDDI Combination Type Severity 
Frequency 
(n=850) 
Percentage 
(%) 
T.Asprin + T.Clopidogrel 
PD Major 245 28.82% 
T.Aspirin + T.Enalapril 
PD Moderate 69 8.11% 
T.Atorvastatin +T.Clopidogrel 
PK Moderate 78 9.17% 
T.Aspirin + T.Atenolol 
PD Moderate 29 2.94% 
T.Clopidogrel +T.Amlodipine 
PK Moderate 80 9.41% 
T.Atenolol + T.Metformin 
PK Major 25 2.94% 
T.Spironolactone +T.Enalapril 
PD Moderate 18 2.11% 
T.Enalapril + T.Metformin 
Unknown Major 15 1.76% 
T.Enalapril + T.Furosemide 
PD Moderate 12 1.41% 
T.Aspirin + T.Spironolactone 
PD Major 41 4.82% 
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Figure 7: Highest potential drug-drug interaction combinations 
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Table 8:Interactive effect, M.O.A, Clinical Management for common potential drug-
drug interactions in cardiology 
PDDI combination Mechanism of 
action 
Interactive Effect 
Clinical 
Management 
T.Asprin + 
T.Clopidogrel 
Increased risk of 
bleeding. 
Additive Effect 
 
Monitor for blood 
counts if co-
administration is 
needed 
T.Aspirin + 
T.Enalapril 
Decreased 
effectiveness of 
enalapril. 
Antagonistic Effect 
Weigh benefit and 
risk 
T.Atorvastatin + 
T.Clopidogrel 
Decreased formation 
of the clopidogrel 
active metabolite 
resulting in higher 
on-treatment platelet 
reactivity. 
Metabolism 
Discontinue the statin 
and substitute a statin 
that is not 
metabolized by 
CYP3A4 (i.e, 
pravastatin or 
rosuvastatin) 
T.Aspirin + 
T.Atenolol 
Decreased 
antihypertensive 
effect. 
Antagonistic Effect 
Monitor for the 
patient’s blood 
counts and dose 
adjustment for beta 
blockers if necessary 
T.Clopidogrel + 
T.Amlodipine 
Decreased 
antiplatelet effect and 
increased risk of 
thrombotic events. 
Inhibit CYP3A 
(Metabolism) 
The addition of 
cilostazol may reduce 
the potential harmful 
interactions 
T.Atenolol + 
T.Metformin 
Result in 
hypoglycemia or 
Altered glucose 
Metabolism 
Monitor for patient’s 
glucose level 
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hyperglycemia 
T.Spironolactone + 
T.Enalapril 
Result in 
hyperkalemia. 
Additive Effect 
Monitor for serum 
potassium level 
T.Enalapril + 
T.Metformin 
Increased risk of 
hypoglycemia. 
Unknown 
Mechanism 
Avoid concurrent use 
T.Enalapril + 
T.Furosemide 
Result in postural 
hypotension 
Synergistic Effect 
Discontinue the 
diuretic 2 or 3 days 
prior to ACEI 
T.Aspirin + 
T.Spironolactone 
Result in 
hyperkalemia, or 
possible 
nephrotoxicity. 
Additive Effect 
Avoid aspirin doses 
of greater than 
650mg daily in adults 
receiving 
spironolactone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Incidence Of Potential Drug–Drug Interactions In Cardiac Patients In A Tertiary Care Hospital 
 
DEPARTMENT OF PHARMACY PRACTICE        56       J.K.K. NATTARAJA COLLEGE OF PHARMACY  
 
 
Table 9: Highest percentage of potential drug-drug interaction combinations 
SI.NO Disease condition pDDIs Combination 
1. Myocardial Infarction 
T.Aspirin 
+ 
T.Clopidogrel, 
T.Atorvastatin 
+ 
T.Clopidogrel. 
2. Hypertension 
T.Aspirin 
+ 
T.Enalapril, 
Tab.Aspirin 
+ 
Tab.Atenolol 
3. Ischaemic Heart Disease T.Atorvastatin + T.Clopidogrel 
 
4. 
Coronary Artery Disease 
T.Spironolactone 
+ 
T.Enalapril 
 
 
5. Chronic Heart Failure 
T.Aspirin 
+  
T.Spironolactone, 
T.Spironolactone 
+ 
T.Enalapril 
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18% 
Types Prevalence of pDDIs 
Major 
Moderate 
Minor 
Table:10Types of Prevalence of pDDIs 
 
SI.NO 
 
Severity of pDDIs 
 
Frequency (n=856) 
 
Percentage% 
1. 
Major 
 
456 
 
53.27% 
2. 
Moderate 
 
251 
 
29.33% 
3. 
Minor 
 
149 
 
17.40% 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Types Prevalence of pDDIs 
 
 
 
 
 
 
 
The Incidence Of Potential Drug–Drug Interactions In Cardiac Patients In A Tertiary Care Hospital 
 
DEPARTMENT OF PHARMACY PRACTICE        58       J.K.K. NATTARAJA COLLEGE OF PHARMACY  
 
Table 11: Classification of Types of pDDIs 
 
 
SI.NO 
 
Frequency (n=360) 
 
Interacting Pairs 
(n=82) 
 
 
Total Number of Interactions 
(n=856) 
 
Percentage% 
PK 256 29.90% 42 
  PD                      456   53.27% 23 
PK + PD 71 8.29% 6 
Unknown 73 8.54% 11 
 
 
 
Fig:9.: Classification of Types of pDDIs 
 
 
 
30% 
53% 
8% 
9% 
Classification of Types of pDDIs 
PK 
PD 
PK + PD 
Unknown 
The Incidence Of Potential Drug–Drug Interactions In Cardiac Patients In A Tertiary Care Hospital 
 
DEPARTMENT OF PHARMACY PRACTICE        59       J.K.K. NATTARAJA COLLEGE OF PHARMACY  
 
Table 12: Classification of PK Interactions 
 
 
Types 
Total Number of 
Occurrences(n =256) 
 
Percentage% 
Absorption 39  15.23% 
Distribution 41 16.01% 
Metabolism 141  55.07% 
Excretion 35  13.67% 
Distribution  
+ 
 Excretion 
- 
 
 
 
 
Figure 10:Classification of PK Interactions 
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Table 13: Classification of PD Interactions 
 
 
 
 
Figure 11:Classification of PD Interactions 
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Types 
Total Number of 
Occurrences(n =456) 
 
Percentage% 
Antagonism  115 25.21% 
Synergism 28  6.14% 
Additive 294 64.47% 
Antagonism +  Additive 19 4.18% 
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Discussion 
Drug interactions are a major area of concern these days for the effective management 
of patient illness. It may create a considerable health hazard to the patients when the risk –
benefit ratio of combining interacting drugs is not accurately estimated. It has already been 
approximated that the effect of drug interactions can range from any minor morbidity to fatal 
consequences. The study of drug-drug, food-drug, and disease-drug interactions and of 
genetic factors affecting pharmacokinetics and pharmacodynamics is expected to improve 
drug safety and will enable individualized drug therapy. 
The present study identified a total of 425 patients were admitted in the department of 
cardiology during the study period. Among these, 425 patients, 360 (84.70%) had found to be 
pDDIs, 856 pDDIs were found in 360 patients (Table 1). Out of which 252 (70.00%) male 
patients found to be higher pDDIs, compared to females,which are similar to the study 
conducted by Sharma et. al
63
., (Table 2). Another study conducted by Murtazaet. al.,
55
 also 
reports that male patients are higher (55.1%).More number of male patients when compared 
to female in the present study may be the primary reason. Another reason possibly will be the 
greater risk of cardiovascular disorders among male gender when compared to female and 
hence there is a need for multiple drugs which ultimately result in drug interactions. 
Our studies revealed that majority of the patients were found to be age group of 60-70 
years (Table 3). A study conducted by Chelkebaet. al.,
67
 reported an age group of 59 – 69 
years whereas, study conducted by Fita et. al.,
68
 reported that majority of patients ages were 
between 70-74 yrs. Older people were at high risk of developing an ADR due to pDDIs for 
several reasons. They are likely to have higher comorbidities and thus take several 
prescriptions and over the counter drugs. As people get older, the liver loses the ability to 
metabolize drugs. Also, older people are more than twice as susceptible to ADRs as younger 
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people. As people age, the amount of water in the body decreases and the amount of fat tissue 
relative to water, increases. Also, as people age, the kidneys are less able to excrete drugs into 
the urine, and the liver is less able to metabolize many drugs. 
The study revealed that 251(69.72%) of cases reported that number of hospital stay 
was between 4-6 days.(Table 4) Lubinga et. al.,
1
 conducted a study which showed that 
majority of the cases, the number of hospital stay were less than 6 days. The likelihood of 
getting the multiple drugs increases with the increased length of hospital stay which in turn 
will increase the likeilhood of pDDIs. 
In our study shows that,51.66% patients were prescribed with more than 7 drugs in 
the cardiology department (Table 5). The study conducted by Andrade et. al.,
69
 which have 
shown  40.6% cases have been reported as the prescribing between 13 to 16 drugs. The more 
the medications that are prescribed, more possibility of polypharmacy. A study determined 
the probability of potential cytochrome P450 (CYP 450) interactions in older hospitalized 
people taking more than five concurrent medicines. Potential drug–drug interactions are 
present in 80% of people taking more than 5 concurrent medicines. People taking 5 
concurrent medicines have a 50% probability of at least one drug interaction, each additional 
medicine adds a 12% increase in risk of drug interactions.
58 
The most common interacting pair of present study was found to be between Aspirin 
and Clopidogrel (Table 7). The study is similar to the study conducted by Murtazaet. al.,
55
 in 
which most common interacting pair were identified as aspirin – clopidogrel followed by 
clopidogrel– Fondaparinux. Another study conducted byPatel et. al.,65 observed an increased 
risk, when aspirin combined with other thrombolytic agent. 
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The prevalence of pDDIs in our study was 53.27%(Table 10).  A similar study was 
performed by Ismail et. al.,
72
showed an overall 77.5%  pDDIs prevalence rate among 
randomly selected cardiac patients. A study conducted by Murtazaet. al.,
55
 in the department 
of cardiology showed that the prevalence rate of pDDIs was 91.6% among the studied cardiac 
patients.  
Out of 360 patients, there was 82 interacting pair identified during the study. Among 
856pDDIs, 256 (29.90%) were pharmacokinetic interactions, 456 (53.27%) were 
pharmacodynamic interactions, 71 (8.29%) showing both mechanisms and 73 (8.54%) were 
unknown mechanism (Table 11). Among 256 pharmacokinetic drug interactions, 39 
(15.23%) were due to absorption, 41 (16.01%) were due to distribution, 141 (55.07%) were 
due to metabolism and 35 (13.67%) were due to excretion (Table 12). Among 456 (53.27%) 
pharmacodynamic interactions, 28 (6.14%) were synergistic, 115 (25.21%) were antagonistic, 
294 (64.47%) were additive and 19 (4.18%)with both additive and antagonistic effects (Table 
13). According to Chavda et al.,
71
among 423 pDDIs, 50.83% were pharmacodynamic drug 
interactions, 38.53% pharmacokinetics, and 10.64% showing both kinds of mechanisms. 
From the 163 pharmacokinetic pDDIs, 45.41% were affected absorption, 28.99% were 
affected metabolism, and 25.60% were affected excretion. Of the 215 
pharmacodynamicpDDIs, 67.44% were synergistic, 30.70% antagonistic and 1.86% unknown 
in nature. The reason for the majority being pharmacodynamic interaction is that these types 
of interactions derive from modification of the action of one drug at the target site by another 
drug, independent of a change in its concentration. This may result in enhanced response 
(synergism), an attenuated response (antagonism) or an abnormal response. 
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Conclusion 
Our study concluded that the overall incidence of pDDIs was very high in the 
Department of Cardiology. The pDDIs were found to be more in males compared to females, 
it was found that incidence of pDDIs was associated with old age, polypharmacy and 
increased lengths of hospital stay. The majority of interactions were pharmacodynamic in 
nature, having major severity. The most of the common pDDIs were betwwen aspirin and 
clopidogrelnd followed by sspirin and Enalapril. The development of such data base in 
hospitals may help for the surveillance of pDDIs in hospitalized cardiac patients. 
The physicians should be aware of interactions among those drugs while prescribing 
for patients and thorough monitoring should be required for the patient safety by the 
implementation of admonitory guidelines and computer-based screening, which might help to 
prevent potentially harmful drug interactions. 
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